UK researchers have dug into the archive to find more cancer samples for sequencing, Nature News reports.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
Two researchers devised a protocol to sequence DNA from ancient samples and tested it on 100-year-old museum specimens.
The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.
The company plans to raise $25 million in a Series B financing round. It is also working on a two-color chemistry and aims to develop an instrument for clinical applications.
The diagnostic, a real-time PCR kit for breast cancer stratification, is being reviewed under a special process for the approval of innovative products.
Earlier this month at AGBT, company researchers presented the new developments, which Thermo Fisher plans to roll out later this year.
They plan to combine Silicon’s DEPArray digital-sorting technology with Macrogen’s NGS systems to develop genomic tests for different cancers.
At the Festival of Genomics conference, experts discussed ongoing issues with developing NGS tests for the clinic, and how they are solving such challenges.
In Nature this week: method to detect single-nucleotide and copy-number alterations in single cells from archival tissue, and more.
The New York Times reports that as China invests in science, it also is dealing with research fraud.
In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.
Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.
The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.